Radiology AI devices are more likely to face FDA recalls, largely due to deviations from intended use and incomplete clinical data.
Key Details
- 1New analysis looked at 903 healthcare AI devices approved by FDA between 1995 and 2024.
- 2Of these, 5% (43 devices) were recalled, with a median recall interval of 458 days.
- 3Radiology comprised 692 of these devices, with a 4.3% (30 devices) recall rate.
- 4Radiology AI devices are 52% more likely to face recall than AI devices in other specialties.
- 5Missing clinical study information and deviations from intended use were major risk factors for recall.
- 6Problems with temperature and labeling led to lower recall risk, while market surveillance flags increased it.
Why It Matters
This study is the first to systematically quantify recall risk factors for AI-enabled devices, highlighting the urgent need for rigorous validation and postmarket surveillance, especially within radiology. Increased transparency and robust premarket evaluation may help mitigate safety risks as AI adoption accelerates.
Source
Radiology Business
Related News
•HealthExec
Mayo Clinic Sued Over Alleged AI Improprieties and Whistleblower Retaliation
A former Mayo Clinic research director sues the institution, alleging retaliation after raising concerns about improper AI use affecting patient safety and data integrity.
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.